TCI使用Cookie來個性化和改善您的用戶體驗(yàn),您可以訪問我們的隱私權(quán)政策 了解更多信息。
Maximum quantity allowed is 999
請選擇數(shù)量
CAS RN: 170787-99-2 | 產(chǎn)品編碼: E1356
Efaproxiral Sodium

純度/分析方法: >98.0%(T)(HPLC)
別名:
- 乙丙昔羅鈉
- RSR 13鈉
- 2-[4-[2-[(3,5-二甲苯基)氨基]-2-氧代乙基]苯氧基]-2-甲基丙酸鈉鹽
- RSR 13 Sodium
- Sodium 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoate
- 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic Acid Sodium Salt
產(chǎn)品文檔:
* 點(diǎn)擊“查詢”可查看預(yù)計(jì)發(fā)貨日期,僅供參考。
* 無具體發(fā)貨日期的情況,如:顯示“8個工作日后發(fā)貨”,將在您訂購日起的8個工作日后發(fā)貨。
* 我們將以最優(yōu)方式從上海/天津兩大倉庫發(fā)貨。國內(nèi)庫存不足,需兩周左右向日本總部調(diào)貨。
* 對于可分裝產(chǎn)品,11:30前的訂單,當(dāng)天發(fā)貨;11:30后的訂單,隔天發(fā)貨。
* 如需大包裝,請點(diǎn)擊“大包裝詢價”按鈕(對于某些產(chǎn)品我們無法提供大包裝)。
* TCI會經(jīng)常復(fù)審儲藏條件以對其進(jìn)行優(yōu)化,請以在線目錄為準(zhǔn),敬請留意。
* 更多信息,請聯(lián)系營業(yè)部:021-67121386 / Sales-CN@TCIchemicals.com 。任何貨期、規(guī)格或包裝方面的需求,請聯(lián)系我們 。
* 無具體發(fā)貨日期的情況,如:顯示“8個工作日后發(fā)貨”,將在您訂購日起的8個工作日后發(fā)貨。
* 我們將以最優(yōu)方式從上海/天津兩大倉庫發(fā)貨。國內(nèi)庫存不足,需兩周左右向日本總部調(diào)貨。
* 對于可分裝產(chǎn)品,11:30前的訂單,當(dāng)天發(fā)貨;11:30后的訂單,隔天發(fā)貨。
* 如需大包裝,請點(diǎn)擊“大包裝詢價”按鈕(對于某些產(chǎn)品我們無法提供大包裝)。
* TCI會經(jīng)常復(fù)審儲藏條件以對其進(jìn)行優(yōu)化,請以在線目錄為準(zhǔn),敬請留意。
* 更多信息,請聯(lián)系營業(yè)部:021-67121386 / Sales-CN@TCIchemicals.com 。任何貨期、規(guī)格或包裝方面的需求,請聯(lián)系我們 。
技術(shù)規(guī)格
Appearance | White to Almost white powder to lump |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 %(calcd.on anh.substance) |
Melting point | 240.0 to 244.0 °C |
Water | max. 13.0 % |
NMR | confirm to structure |
物性(參考值)
GHS
相關(guān)法規(guī)
新化學(xué)物質(zhì)備案回執(zhí)號 | B1A232216042 |
運(yùn)輸信息
監(jiān)管條件代碼(*) |
應(yīng)用
Efaproxiral Sodium: Developed as an Allosteric Modifier of Hemoglobin and a Radiation Sensitizer
Efaproxiral sodium (RSR 13 sodium), an analogue of the antilipemic agent bezafibrate [B3346], was developed as an allosteric modifier of hemoglobin1,2) and a radiation sensitizer.3) In the 2000s, efaproxiral sodium was tested in a clinical trial to increase the efficacy of certain chemotherapy agents which have reduced efficacy against hypoxic tumors, and can thus be made more effective by increased offloading of oxygen from hemoglobin-bound oxygen into the tumor tissues.4) But the clinical trial was dropped out in Phase III trials. In 2009, Efaproxiral was added to the World Anti-Doping Agency (WADA) list of Prohibited Substances as an artificially enhancer of the uptake, transport or delivery of oxygen.5) (The product is for research purpose only.)
References
- 1) Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents
- 2) Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats
- 3) Radiation sensitization with redox modulators: a promising approach (a review)
- 4) Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo
- 5) Preventive doping control screening analysis of prohibited substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight mass spectrometry
產(chǎn)品文檔 (部分產(chǎn)品的分析圖譜無法提供,敬請諒解。)
化學(xué)品安全說明書(SDS)
技術(shù)規(guī)格
CoA及其他文檔
示例 CoA
可下載CoA示例。注:該示例不一定是最新批次的CoA。
目前沒有該產(chǎn)品的 CoA?示例。